Literature DB >> 10328994

Differential effects of some cell signalling inhibitors upon nitric oxide synthase expression and nuclear factor-kappaB activation induced by lipopolysaccharide in rat aortic smooth muscle cells.

J Zhou1, A D Struthers, G A Lyles.   

Abstract

Treatment of rat aortic smooth muscle cells (RASMC) with 1 or 100 microg ml-1 lipopolysaccharide (LPS) for 20-24 h led to expression of the inducible form of nitric oxide synthase (iNOS) as detected by Western blotting for iNOS protein, and by determination of increased cellular nitrite formation. LPS-induced nitrite production was inhibited almost completely by concomitant treatment of cells with LPS and either (a) pyrrolidine dithiocarbamate (PDTC, 25 microm), an antioxidant inhibitor of NF-kappaB activation; (b) N-tosyl-L-phenylalanine chloromethyl ketone (TPCK, 20 and 40 microm), a proteasomal inhibitor which prevents NF-kappaB activation; (c) nordihydroguaiaretic acid (NDGA, 10 and 50 microm), a lipoxygenase inhibitor; or (d) apocynin (2, 3.5 and 5 m m), an inhibitor of NADPH oxidase. Gel-shift assays using nuclear protein extracts incubated with a 32P-labelled DNA binding probe for NF-kappaB detected two electrophoretically separable complexes containing NF-kappaB. A faster migrating complex obtained when using both LPS-treated and untreated cells appeared to represent a basal or constitutive NF-kappaB activity, whereas a slower band was found only after LPS-treatment. The latter band was abolished when using cells treated for 1 h with LPS in the presence of PDTC (25 microm) or TPCK (20 microm), but was not inhibited by NDGA (50 microm) or apocynin (3.5 m m). The basal band was unaffected by any of the cell signalling inhibitors. Densitometry of Western blots indicated that LPS-induced iNOS protein expression was inhibited to a similar extent (between 74 and 87%) by the latter concentrations of PDTC, TPCK, NDGA and apocynin. The ability of PDTC and TPCK to abolish LPS-specific NF-kappaB activation, while also producing considerable inhibition of iNOS protein expression and nitrite formation, suggests that induction of iNOS by LPS in RASMC involves NF-kappaB-dependent transcription. However, the failure of NDGA and apocynin to prevent NF-kappaB activation, at least during early stages (up to 1 h) of its nuclear accumulation, suggests that these agents may affect cell signalling pathways which regulate iNOS induction by another mechanism to be determined. Copyright 1999 The Italian Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10328994     DOI: 10.1006/phrs.1998.0450

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  5 in total

1.  Effects of aldosterone and related steroids on LPS-induced increased expression of inducible NOS in rat aortic smooth muscle cells.

Authors:  V Godfrey; A L Martin; A D Struthers; G A Lyles
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

2.  Reduction of Ether-Type Glycerophospholipids, Plasmalogens, by NF-κB Signal Leading to Microglial Activation.

Authors:  Md Shamim Hossain; Yuichi Abe; Fatma Ali; Mohammed Youssef; Masanori Honsho; Yukio Fujiki; Toshihiko Katafuchi
Journal:  J Neurosci       Date:  2017-03-14       Impact factor: 6.167

3.  Effects of aminoguanidine on nitric oxide production induced by inflammatory cytokines and endotoxin in cultured rat hepatocytes.

Authors:  G L Zhang; Y H Wang; H L Teng; Z B Lin
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

4.  Ethanol preconditioning protects against ischemia/reperfusion-induced brain damage: role of NADPH oxidase-derived ROS.

Authors:  Qun Wang; Albert Y Sun; Agnes Simonyi; Theodore J Kalogeris; Dennis K Miller; Grace Y Sun; Ronald J Korthuis
Journal:  Free Radic Biol Med       Date:  2007-07-04       Impact factor: 7.376

5.  Limb ischemic preconditioning protects against contrast-induced nephropathy via renalase.

Authors:  Feng Wang; Jianyong Yin; Zeyuan Lu; Guangyuan Zhang; Junhui Li; Tao Xing; Shougang Zhuang; Niansong Wang
Journal:  EBioMedicine       Date:  2016-05-18       Impact factor: 8.143

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.